How to Get Soolantra Online in Bologna

If you are searching for Soolantra online in Bologna to manage persistent facial redness, papules, or pustules, accessing a timely dermatology appointment in Emilia-Romagna can take weeks. Hi-Doctor provides a direct online consultation with EU-licensed doctors for a 40 € one-off fee. While Hi-Doctor does not prescribe brand-name Soolantra monotherapy, our physicians clinically evaluate your skin photos and symptoms to prescribe evidence-based topical treatments—such as compounded ivermectin 1% combined with metronidazole 0.75% and niacinamide 2%—when clinically appropriate. A doctor reviews within 24 hours and issues a prescription when clinically appropriate, which can be presented at any EU pharmacy, where the pharmacist may dispense a locally marketed equivalent.

• Flat fee: 40 € one-off medical consultation with no ongoing subscription.
• Fee protection: The 40 EUR consultation fee is refunded in full if the doctor does not issue a prescription.
• Digital prescription: Official REMPE prescription issued via downloadable PDF in under 24 hours when approved.
• Asynchronous care: Completed via structured medical questionnaire with photo upload—no video calls or waiting rooms.

How it works — get your consultation in 4 steps

Consulting an EU-licensed doctor online avoids clinic waiting lists in Bologna while maintaining medical rigor through structured clinical branching and visual assessment.

1. Complete the medical questionnaire: Answer questions regarding your skin history, rosacea symptoms, flare triggers, and prior treatments.
2. Upload skin photos: Submit clear, well-lit photographs of the affected areas of your face for doctor evaluation.
3. Doctor review within 24 hours: An EU-licensed doctor reviews your clinical data and skin images to determine appropriate topical therapy.
4. Receive your REMPE prescription: If approved, your REMPE prescription PDF is delivered securely to your account inbox to present at a pharmacy.

Who qualifies

Online rosacea consultations are designed for adult patients dealing with mild-to-moderate facial rosacea. Eligibility is assessed individually by an EU-licensed doctor based on symptom presentation and medical history.

Rosacea is a chronic inflammatory condition influenced by external and internal triggers. Identifying and managing triggers such as ultraviolet radiation, alcohol, hot beverages, spicy foods, temperature shifts, and psychological stress is essential alongside topical pharmacotherapy.

Certain presentations fall outside the scope of remote care. Hi-Doctor evaluates and treats mild-to-moderate topical conditions only:

• Topical treatment only: Oral antibiotics, oral isotretinoin, and systemic therapies are not prescribed online.
• In-person referrals: Severe, nodular, or cystic disease, ocular rosacea (eye involvement), rhinophyma (tissue hypertrophy), and vascular laser/IPL therapy require an in-person medical assessment.

What Soolantra actually does

Soolantra is the commercial brand name for ivermectin 1% topical cream. Ivermectin targets papulopustular rosacea through a dual mechanism: reducing the density of microscopic Demodex mites residing in hair follicles and exerting an anti-inflammatory effect by suppressing inflammatory cytokines.

Hi-Doctor handles treatment options transparently: our medical team does not prescribe brand-name Soolantra monotherapy. Instead, our doctors prescribe targeted compounded alternatives or established first-line topicals that address multiple rosacea pathways simultaneously.

Treatment	Active Ingredients	Mechanism of Action	Primary Clinical Target
Brand Soolantra	Ivermectin 1%	Anti-parasitic (anti-Demodex) and anti-inflammatory monotherapy	Papulopustular rosacea (Not prescribed by Hi-Doctor)
Compounded Papulopustular Gel	Ivermectin 1% + Metronidazole 0.75% + Niacinamide 2%	Dual antimicrobial/antiparasitic action plus skin barrier support	Inflammatory bumps, pustules, and localized erythema
Compounded Erythema Cream	Metronidazole 0.75% + Niacinamide 4% + Azelaic Acid 10% + Allantoin 0.5%	Anti-inflammatory, redness reduction, and soothing hydration	Persistent central facial erythema and skin sensitivity
Azelaic Acid 15% Gel	Azelaic acid 15%	Inhibits follicular keratinisation and reduces inflammatory lesions	Mild-to-moderate papulopustular rosacea

Rosacea is a manageable condition rather than a curable one; ongoing maintenance is typically required, and relapses can occur upon stopping therapy. Visible improvement with topical ivermectin combinations is commonly observed between weeks 4 and 8, with peak therapeutic response assessed around weeks 12 to 16.

Side effects and when to stop

Most patients tolerate topical rosacea treatments well, but localized skin reactions can occur during the initial phase of application.

• Common reactions: Mild burning, stinging, skin dryness, itching, or temporary localized redness at the application site.
• Transient worsening: A brief increase in inflammatory papules may occur during the first 1 to 2 weeks as Demodex mite load decreases.
• When to discontinue: Stop treatment and seek in-person medical evaluation immediately if you experience severe contact dermatitis, facial swelling, eye irritation, or unmanageable burning.

Why Hi-Doctor vs. walking into a clinic

Securing a dermatology consultation in Bologna through traditional clinics often involves prolonged waiting times or substantial private fees. Hi-Doctor provides a standardized, asynchronous medical review conducted entirely online.

Over 50,000 patients have accessed asynchronous medical care through Hi-Doctor, backed by a 4.8/5 Trustpilot rating across Europe.

All clinical evaluations are performed by EU-licensed doctors adhering to EU data-protection standards under GDPR. When clinically indicated, prescriptions are issued using the Spanish official REMPE electronic prescription standard. Under Directive 2011/24/EU, patients possess the right to present cross-border prescriptions within the EU, containing prescriber and product details as set out in Commission Implementing Directive 2012/52/EU.